Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 3
Submit an article Journal homepage
2,368
Views
35
CrossRef citations to date
0
Altmetric
Original Research

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Anje CauwelsCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Sandra Van LintCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Geneviève GarcinUniversity Montpellier, Place Eugène Bataillon, Montpellier, FranceView further author information
,
Jennyfer BultinckCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium;Present address: Oxyrane, Zwijnaarde-Gent, BelgiumView further author information
,
Franciane PaulUniversity Montpellier, Place Eugène Bataillon, Montpellier, FranceView further author information
,
Sarah GerloCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
José Van der HeydenCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Yann BordatUniversity Montpellier, Place Eugène Bataillon, Montpellier, FranceView further author information
,
Dominiek CatteeuwCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Lode De CauwerCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium;Present address: Argenx BVBA, Zwijnaarde-Gent, BelgiumORCID Iconhttp://orcid.org/0000-0002-6928-8271View further author information
ORCID Icon,
Elke RoggeCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Annick VerheeCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumView further author information
,
Gilles UzéUniversity Montpellier, Place Eugène Bataillon, Montpellier, FranceView further author information
&
Jan TavernierCytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent University, Ghent, BelgiumCorrespondence[email protected]
View further author information
 show all
Article: e1398876 | Received 29 Aug 2017, Accepted 25 Oct 2017, Published online: 27 Nov 2017

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W.M. De Groof & Nick Devoogdt. (2023) Current status and future expectations of nanobodies in oncology trials. Expert Opinion on Investigational Drugs 32:8, pages 705-721.
Read now
Danielle M. Dicara, Sunil Bhakta, Mary Ann Go, James Ziai, Ron Firestein, Bill Forrest, Chen Gu, Steven R. Leong, Genee Lee, Shang-Fan Yu, Andrew G. Polson & Nicholas J. Agard. (2022) Development of T-cell engagers selective for cells co-expressing two antigens. mAbs 14:1.
Read now
Meixiao Long, Alice S. Mims & Zihai Li. (2022) Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunological Investigations 51:8, pages 2176-2214.
Read now
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now
Isaure Vanmeerbeek, Jenny Sprooten, Dirk De Ruysscher, Sabine Tejpar, Peter Vandenberghe, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2020) Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology 9:1.
Read now
Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Abhishek D. Garg. (2019) Trial watch: dendritic cell vaccination for cancer immunotherapy. OncoImmunology 8:11.
Read now

Articles from other publishers (29)

Sandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, Niels Vandamme, Stephane Plaisance, Annick Verhee, Dominiek Catteeuw, Elke Rogge, Jennifer De Geest, Nele Vanderroost, Jana Roels, Yvan Saeys, Gilles Uzé, Niko Kley, Anje Cauwels & Jan Tavernier. (2023) A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state. Molecular Cancer 22:1.
Crossref
Paul Noe, Joy H. Wang, Kyu Chung, Zhiyong Cheng, Jessica J. Field, Xiaomeng Shen, Christa L. Cortesio, Cinthia V. Pastuskovas, Hyewon Phee, Kristin V. Tarbell, Jackson G. Egen & Amy-Jo Casbon. (2023) Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies. Frontiers in Immunology 14.
Crossref
Ali Razaghi, Mickaël Durand-Dubief, Nele Brusselaers & Mikael Björnstedt. (2023) Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Frontiers in Immunology 14.
Crossref
Jiaqi Zhai, Xi Gu, Yang Liu, Yueting Hu, Yi Jiang & Zhenyong Zhang. (2023) Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology 14.
Crossref
Jiage Ding, Yanyan Zheng, Gang Wang, Junnian Zheng & Dafei Chai. (2022) The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:5, pages 188763.
Crossref
Mushtaq Ahmad Nengroo, Ayushi Verma & Dipak Datta. (2022) Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine 156, pages 155916.
Crossref
Kazuki Sakatoku, Yasuhiro Nakashima, Joji Nagasaki, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Hideo Koh, Masayuki Hino & Hirohisa Nakamae. (2022) Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia. Cancer Science 113:7, pages 2246-2257.
Crossref
Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W.M. De Groof, Yannick De Vlaeminck, Ahmet Krasniqi, Kim De Veirman, Cleo Goyvaerts, Matthias D’Huyvetter, Sophie Hernot, Nick Devoogdt & Karine Breckpot. 2022. New Antibody Formats. New Antibody Formats 143 199 .
Aliyah B. Silver, Elissa K. Leonard, Joseph R. Gould & Jamie B. Spangler. (2021) Engineered antibody fusion proteins for targeted disease therapy. Trends in Pharmacological Sciences 42:12, pages 1064-1081.
Crossref
Anje Cauwels, Sandra Van Lint, Elke Rogge, Annick Verhee, Bram Van Den Eeckhout, Shengru Pang, Marco Prinz, Niko Kley, Gilles Uzé & Jan Tavernier. (2021) Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE. Scientific Reports 11:1.
Crossref
Daniel Herranz. (2021) INTERFERing with the progression of T-cell acute lymphoblastic leukemia: a multifaceted therapy. Haematologica 107:6, pages 1232-1234.
Crossref
Steven Goossens, Anje Cauwels, Tim Pieters, Renate De Smedt, Sara T’Sas, André Almeida, Willem Daneels, Pieter Van Vlierberghe & Jan Tavernier. (2021) Direct and indirect anti-leukemic properties of activity-on-target interferons for the treatment of T-cell acute lymphoblastic leukemia. Haematologica 107:6, pages 1448-1453.
Crossref
Sheila Dakhel, Christian Lizak, Mattia Matasci, Jacqueline Mock, Alessandra Villa, Dario Neri & Samuele Cazzamalli. (2021) An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease. International Journal of Molecular Sciences 22:18, pages 10020.
Crossref
Yong Liang, Raquibul Hannan & Yang-Xin Fu. (2021) Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity. Clinical Cancer Research 27:14, pages 3818-3824.
Crossref
Baptiste Gouyou, Tiziano Ongaro, Samuele Cazzamalli, Roberto De Luca, Anne Kerschenmeyer, Philippe Valet, Alessandra Villa, Dario Neri & Mattia Matasci. (2021) Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis. Experimental Biology and Medicine 246:8, pages 940-951.
Crossref
Erin Runbeck, Silvia Crescioli, Sophia N. Karagiannis & Sophie Papa. (2021) Utilizing Immunocytokines for Cancer Therapy. Antibodies 10:1, pages 10.
Crossref
Bram Van Den Eeckhout, Jan Tavernier & Sarah Gerlo. (2021) Interleukin-1 as Innate Mediator of T Cell Immunity. Frontiers in Immunology 11.
Crossref
Lindsey E. Fox, Marissa C. Locke & Deborah J. Lenschow. (2020) Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. Frontiers in Immunology 11.
Crossref
Jacqueline Mock, Marco Stringhini, Alessandra Villa, Michael Weller, Tobias Weiss & Dario Neri. (2020) An engineered 4-1BBL fusion protein with “activity on demand”. Proceedings of the National Academy of Sciences 117:50, pages 31780-31788.
Crossref
Keke Li, Shuang Zhao, Jing Long, Juan Su, Lisha Wu, Juan Tao, Jianda Zhou, JiangLin Zhang, Xiang Chen & Cong Peng. (2020) A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. Cancer Cell International 20:1.
Crossref
Bram Van Den Eeckhout, Lien Van Hoecke, Elianne Burg, Sandra Van Lint, Frank Peelman, Niko Kley, Gilles Uzé, Xavier Saelens, Jan Tavernier & Sarah Gerlo. (2020) Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant. npj Vaccines 5:1.
Crossref
Anje Cauwels & Jan Tavernier. (2020) Tolerizing Strategies for the Treatment of Autoimmune Diseases: From ex vivo to in vivo Strategies. Frontiers in Immunology 11.
Crossref
Leander Huyghe, Alexander Van Parys, Anje Cauwels, Sandra Van Lint, Stijn De Munter, Jennyfer Bultinck, Lennart Zabeau, Jeroen Hostens, An Goethals, Nele Vanderroost, Annick Verhee, Gilles Uzé, Niko Kley, Frank Peelman, Bart Vandekerckhove, Peter Brouckaert & Jan Tavernier. (2020) Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies. EMBO Molecular Medicine 12:2.
Crossref
Edwin Roger Parra, Mei Jiang, Luisa Solis, Barbara Mino, Caddie Laberiano, Sharia Hernandez, Swati Gite, Anuj Verma, Michael Tetzlaff, Cara Haymaker, Auriole Tamegnon, Jaime Rodriguez-Canales, Clifford Hoyd, Chantale Bernachez & Ignacio Wistuba. (2020) Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. Cancers 12:2, pages 255.
Crossref
Eleonora Aricò, Luciano Castiello, Imerio Capone, Lucia Gabriele & Filippo Belardelli. (2019) Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers 11:12, pages 1943.
Crossref
Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, Wei Xiao, Priscilla S. Redd, Asha Nayak-Kapoor, Gang Zhou & Kebin Liu. (2019) Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Jean-Charles Cancel, Karine Crozat, Marc Dalod & Raphaël Mattiuz. (2019) Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?. Frontiers in Immunology 10.
Crossref
Anje Cauwels, Sandra Van Lint, Dominiek Catteeuw, Shengru Pang, Franciane Paul, Elke Rogge, Annick Verhee, Marco Prinz, Niko Kley, Gilles Uzé & Jan Tavernier. (2019) Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. Journal of Autoimmunity 97, pages 70-76.
Crossref
Pedro Berraondo, Miguel F. Sanmamed, María C Ochoa, Iñaki Etxeberria, Maria A. Aznar, José Luis Pérez-Gracia, María E. Rodríguez-Ruiz, Mariano Ponz-Sarvise, Eduardo Castañón & Ignacio Melero. (2018) Cytokines in clinical cancer immunotherapy. British Journal of Cancer 120:1, pages 6-15.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.